Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Progress of Pruritus Research in Atopic Dermatitis

  • Received : 2010.07.16
  • Accepted : 2010.07.21
  • Published : 2010.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Atopic dermatitis is a common skin disease affecting up to 10% of children and approximately 2% of adults. Atopic dermatitis exhibits four major symptoms, including intense itching, dry skin, redness and exudation. The "itch-scratch-itch" cycle is one of the major features in atopic dermatitis. The pathophysiology and neurobiology of pruritus is unclear. Currently there are no single and universally effective pharmacological antipruritic drugs for treatment of atopic dermatitis. Thus, controlling of itch is a very important unmet need in patients suffering from atopic dermatitis. This article will update progress during the past 10 years of research in the field of pruritus of atopic dermatitis, focusing on aspects of pruritogens (including inflammatory lipids, histamine, serotonin, proteinases, proteinase-activating receptors, neurotransmitters, neuropeptides, and opioid peptides), antipruritic therapies, and emerging new targets. Based on recent progress, researchers expect to identify exciting possibilities for improved treatments and to develop new antipruritic drugs acting through novel targets, such as histamine H4 receptor, gastrin-releasing peptide receptor, MrgprA3, thromboxane A2 receptor and the putative SPC receptor.

Keywords

References

  1. Abeck, D., Andersson, T., Grosshans, E., Jablonska, S., Kragballe,K., Vahlquist, A., Schmidt, T., Dupuy, P. and Ring, J.(1997). Topical application of a platelet-activating factor (PAF) antagonist in atopic dermatitis. Acta. Derm. Venereol. 77,449-451.
  2. Alenmyr, L., Hogestatt, E. D., Zygmunt, P. M. and Greiff, L.(2009). TRPV1-mediated itch in seasonal allergic rhinitis.Allergy 64, 807-810. https://doi.org/10.1111/j.1398-9995.2009.01937.x
  3. Andoh, T. (2008). Mechanisms of cutaneous itch: new itch mediators and enhancement factors produced by keratinocytes.Nippon Yakurigaku Zasshi 131, 361-366. https://doi.org/10.1254/fpj.131.361
  4. Andoh, T. and Kuraishi, Y. (1998). Intradermal leukotriene B4, but not prostaglandin E2, induces itch-associated responses in mice. Eur. J. Pharmacol. 353, 93-96. https://doi.org/10.1016/S0014-2999(98)00440-3
  5. Andoh, T. and Kuraishi, Y. (2005). Expression of BLT1 leukotriene B4 receptor on the dorsal root ganglion neurons in mice.Brain Res. Mol. Brain Res. 137, 263-266. https://doi.org/10.1016/j.molbrainres.2005.02.029
  6. Andoh, T., Nishikawa, Y., Yamaguchi-Miyamoto, T., Nojima, H.,Narumiya, S. and Kuraishi, Y. (2007). Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice. J. Invest Dermatol. 127, 2042-2047. https://doi.org/10.1038/sj.jid.5700810
  7. Andoh, T., Saito, A. and Kuraishi, Y. (2009). Leukotriene B(4) mediates sphingosylphosphorylcholine-induced itch-associated responses in mouse skin. J. Invest. Dermatol. 129, 2854-2860. https://doi.org/10.1038/jid.2009.155
  8. Badertscher, K., Bronnimann, M., Karlen, S., Braathen, L. R.and Yawalkar, N. (2005). Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis. Arch. Dermatol. Res. 296, 503-506. https://doi.org/10.1007/s00403-005-0542-3
  9. Ballmer-Weber, B. K. and Dummer, R. (2007). Pruritus in frequent skin diseases and therapeutic options. Praxis (Bern1994) 96, 107-111. https://doi.org/10.1024/1661-8157.96.4.107
  10. Biro, T., Toth, B. I., Marincsak, R., Dobrosi, N., Geczy, T. andPaus, R. (2007). TRP channels as novel players in the pathogenesis and therapy of itch. Biochim. Biophys. Acta. 1772, 1004-1021. https://doi.org/10.1016/j.bbadis.2007.03.002
  11. Capella, G. L., Grigerio, E. and Altomare, G. (2001). A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur. J. Dermatol. 11, 209-213.
  12. Carucci, J. A., Washenik, K., Weinstein, A., Shupack, J. andCohen, D. E. (1998). The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch. Dermatol. 134, 785-786. https://doi.org/10.1001/archderm.134.7.785
  13. Choi, H., Kim, S., Kim, H. J., Kim, K. M., Lee, C. H., Shin, J. H.and Noh, M. (2010). Sphingosylphosphorylcholine downregulates filaggrin gene transcription through NOX5-based NADPH oxidase and cyclooxygenase-2 in human keratinocytes. Biochem. Pharmacol. 80, 95-103. https://doi.org/10.1016/j.bcp.2010.03.009
  14. Cowden, J. M., Zhang, M., Dunford, P. J. and Thurmond, R. L.(2010). The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J. Invest. Dermatol. 130, 1023-1033. https://doi.org/10.1038/jid.2009.358
  15. Czarnetzki, B. M. and Csato, M. (1989). Comparative studies of human eosinophil migration towards platelet-activating factor and leukotriene B4. Int. Arch. Allergy Appl. Immunol. 88,191-193. https://doi.org/10.1159/000234782
  16. Daly, B. M. and Shuster, S. (2000). Antipruritic action of thalidomide.Acta. Derm. Venereol. 80, 24-25. https://doi.org/10.1080/000155500750012450
  17. Davis, M. P., Frandsen, J. L., Walsh, D., Andresen, S. andTaylor, S. (2003). Mirtazapine for pruritus. J. Pain Symptom. Manage 25, 288-291. https://doi.org/10.1016/S0885-3924(02)00645-0
  18. Dawn, A. G. and Yosipovitch, G. (2006). Butorphanol for treatment of intractable pruritus. J. Am. Acad. Dermatol. 54,527-531. https://doi.org/10.1016/j.jaad.2005.12.010
  19. de Oliveira, M. S., Cechim, G., Braganhol, E., Santos, D. G.,Meurer, L., de Castro, C. G. Jr., Brunetto, A. L., Schwartsmann,G., Battastini, A. M., Lenz, G. and Roesler, R. (2009).Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. J. Neurooncol. 93, 191-201. https://doi.org/10.1007/s11060-008-9775-2
  20. Dhaka, A., Viswanath, V. and Patapoutian, A. (2006). Trp ion channels and temperature sensation. Annu. Rev. Neurosci.29, 135-161. https://doi.org/10.1146/annurev.neuro.29.051605.112958
  21. Dunford, P. J., Williams, K. N., Desai, P. J., Karlsson, L.,McQueen, D. and Thurmond, R. L. (2007). Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J. Allergy Clin. Immunol. 119, 176-183. https://doi.org/10.1016/j.jaci.2006.08.034
  22. Ellis, C. N., Drake, L. A., Prendergast, M. M., Abramovits, W.,Boguniewicz, M., Daniel, C. R., Lebwohl, M., Stevens, S. R.,Whitaker-Worth, D. L., Cheng, J. W. and Tong, K. B. (2002).Cost of atopic dermatitis and eczema in the United States. J. Am. Acad. Dermatol. 46, 361-370. https://doi.org/10.1067/mjd.2002.120528
  23. Figueiredo, A., Ribeiro, C. A., Goncalo, M., Almeida, L., Poiares-Baptista, A. and Teixeira, F. (1990). Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam. Clin. Pharmacol. 4, 147-158. https://doi.org/10.1111/j.1472-8206.1990.tb00482.x
  24. Fitzsimons, E. J., Dagg, J. H. and McAllister, E. J. (1981).Pruritus of polycythaemia vera: a place for pizotifen? Br. Med. J. (Clin Res Ed) 283, 277.
  25. Fjellner, B. and Hagermark, O. (1979). Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement. Acta. Derm. Venereol. 59, 505-512.
  26. Fjellner, B. and Hagermark, O. (1985). Experimental pruritus evoked by platelet activating factor (PAF-acether) in human skin. Acta. Derm. Venereol. 65, 409-412.
  27. Folster-Holst, R. and Christophers, E. (2001). Antipruritic therapy in atopic eczema. Hautarzt. 52, 853-861. https://doi.org/10.1007/s001050170046
  28. Gazerani, P., Pedersen, N. S., Drewes, A. M. and Arendt-Nielsen, L. (2009). Botulinum toxin type A reduces histamineinduced itch and vasomotor responses in human skin. Br. J. Dermatol. 161, 737-745. https://doi.org/10.1111/j.1365-2133.2009.09305.x
  29. Greaves, M. W. (2007). Recent advances in pathophysiology and current management of itch. Ann. Acad. Med. Singapore 36, 788-792.
  30. Gunal, A. I., Ozalp, G., Yoldas, T. K., Gunal, S. Y., Kirciman, E.and Celiker, H. (2004). Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol. Dial. Transplant 19, 3137-3139. https://doi.org/10.1093/ndt/gfh496
  31. Hanifin, J. M., Chan, S. C., Cheng, J. B., Tofte, S. J., Henderson,W. R. Jr., Kirby, D. S. and Weiner, E. S. (1996). Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J. Invest. Dermatol.107, 51-56. https://doi.org/10.1111/1523-1747.ep12297888
  32. Hashimoto, T., Ohata, H. and Momose, K. (2004). Itch-scratch responses induced by lysophosphatidic acid in mice. Pharmacology72, 51-56. https://doi.org/10.1159/000078632
  33. Hashimoto, T., Ohata, H., Momose, K. and Honda, K. (2005).Lysophosphatidic acid induces histamine release from mast cells and skin fragments. Pharmacology 75, 13-20. https://doi.org/10.1159/000085784
  34. Heyer, G. R. and Hornstein, O. P. (1999). Recent studies of cutaneous nociception in atopic and non-atopic subjects. J. Dermatol. 26, 77-86. https://doi.org/10.1111/j.1346-8138.1999.tb03516.x
  35. Imokawa, G., Takagi, Y., Higuchi, K., Kondo, H. and Yada, Y.(1999). Sphingosylphosphorylcholine is a potent inducer of intercellular adhesion molecule-1 expression in human keratinocytes. J. Invest. Dermatol. 112, 91-96. https://doi.org/10.1046/j.1523-1747.1999.00462.x
  36. Jiang, J., Kuhara, T., Ueki, R., Zheng, Y., Suto, H., Ikeda, S. andOgawa, H. (2007). Inhibitory effects of paroxetine on the development of atopic dermatitis-like lesions in NC/Nga mice. J. Dermatol. Sci. 47, 244-247. https://doi.org/10.1016/j.jdermsci.2007.05.006
  37. Jones, E. A. and Bergasa, N. V. (2000). Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis.Can. J. Gastroenterol. 14, 33-40. https://doi.org/10.1155/2000/747495
  38. Kim, B. M., Lee, S. H., Shim, W. S. and Oh, U. (2004). HistamineinducedCa(2＋) influx via the PLA(2)/lipoxygenase/TRPV1 pathway in rat sensory neurons. Neurosci. Lett. 361,159-162. https://doi.org/10.1016/j.neulet.2004.01.019
  39. Kim, D. K., Kim, H. J., Kim, H., Koh, J. Y., Kim, K. M., Noh, M.S., Kim, J. J. and Lee, C. H. (2008a). Involvement of serotonin receptors 5-HT1 and 5-HT2 in 12(S)-HPETEinduced scratching in mice. Eur. J. Pharmacol. 579, 390-394. https://doi.org/10.1016/j.ejphar.2007.11.005
  40. Kim, D. K., Kim, H. J., Sung, K. S., Kim, H., Cho, S. A., Kim, K.M., Lee, C. H. and Kim, J. J. (2007). 12(S)-HPETE induces itch-associated scratchings in mice. Eur. J. Pharmacol. 554,30-33. https://doi.org/10.1016/j.ejphar.2006.09.057
  41. Kim, H. J., Kim, D. K., Kim, H., Koh, J. Y., Kim, K. M., Noh, M.S., Lee, S., Kim, S., Park, S. H., Kim, J. J., Kim, S. Y. andLee, C. H. (2008b). Involvement of the BLT2 receptor in the itch-associated scratching induced by 12-(S)-lipoxygenase products in ICR mice. Br. J. Pharmacol. 154, 1073-1078. https://doi.org/10.1038/bjp.2008.220
  42. Kim, H. J., Kim, H., Han, E. S., Park, S. M., Koh, J. Y., Kim, K.M., Noh, M. S., Kim, J. J. and Lee, C. H. (2008c). Characterizations of sphingosylphosphorylcholine-induced scratching responses in ICR mice using naltrexon, capsaicin, ketotifen and Y-27632. Eur. J. Pharmacol. 583, 92-96. https://doi.org/10.1016/j.ejphar.2008.01.005
  43. Kim, H. J., Kim, K. M., Koh, J. Y., Noh, M. S., Park, M. K., Lee,H. J., Kim, S. Y. and Lee, C. H. (2010). Sphingosylphos-phorylcholine induces degranulation of mast cells in the skin and plasma exudation in the ears of mice. J. Dermatol. Sci.57, 57-59. https://doi.org/10.1016/j.jdermsci.2009.09.007
  44. Leung, D. Y. and Soter, N. A. (2001). Cellular and immunologic mechanisms in atopic dermatitis. J. Am. Acad. Dermatol. 44,S1-S12. https://doi.org/10.1067/mjd.2001.109815
  45. Lewis-Jones, S. (2005). Measuring the burden of atopic eczema in young children and the family unit. J. Invest. Dermatol. 125, viii.
  46. Li, W. H., Lee, Y. M., Kim, J. Y., Kang, S., Kim, S., Kim, K. H.,Park, C. H. and Chung, J. H. (2007). Transient receptor potential vanilloid-1 mediates heat-shock-induced matrix metalloproteinase-1 expression in human epidermal keratinocytes.J. Invest. Dermatol. 127, 2328-2335. https://doi.org/10.1038/sj.jid.5700880
  47. Liu, Q., Tang, Z., Surdenikova, L., Kim, S., Patel, K. N., Kim, A.,Ru, F., Guan, Y., Weng, H. J., Geng, Y., Undem, B. J.,Kollarik, M., Chen, Z. F., Anderson, D. J. and Dong, X.(2009). Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell 139,1353-1365. https://doi.org/10.1016/j.cell.2009.11.034
  48. Lovell, C. R., Burton, P. A., Duncan, E. H. and Burton, J. L.(1976). Prostaglandins and pruritus. Br. J. Dermatol. 94,273-275. https://doi.org/10.1111/j.1365-2133.1976.tb04383.x
  49. Lynde, C. B., Kraft, J. N. and Lynde, C. W. (2008). Novel agents for intractable itch. Skin Therapy Lett. 13, 6-9.
  50. Malekzad, F., Arbabi, M., Mohtasham, N., Toosi, P., Jaberian,M., Mohajer, M., Mohammadi, M. R., Roodsari, M. R. andNasiri, S. (2009). Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. J. Eur. Acad. Dermatol. Venereol. 23, 948-950. https://doi.org/10.1111/j.1468-3083.2009.03129.x
  51. Metze, D., Reimann, S., Beissert, S. and Luger, T. (1999).Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J. Am. Acad. Dermatol. 41, 533-539.
  52. Miyoshi, M., Sakurai, T. and Kodama, S. (1999). Clinical evaluation of urinary leukotriene E4 levels in children with atopic dermatitis. Arerugi. 48, 1148-1152.
  53. Neisius, U., Olsson, R., Rukwied, R., Lischetzki, G. and Schmelz,M. (2002). Prostaglandin E2 induces vasodilation and pruritus, but no protein extravasation in atopic dermatitis and controls. J. Am. Acad. Dermatol. 47, 28-32. https://doi.org/10.1067/mjd.2002.120462
  54. Okuno, T., Iizuka, Y., Okazaki, H., Yokomizo, T., Taguchi, R.and Shimizu, T. (2008). 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J. Exp. Med. 205, 759-766. https://doi.org/10.1084/jem.20072329
  55. Peier, A. M., Reeve, A. J., Andersson, D. A., Moqrich, A.,Earley, T. J., Hergarden, A. C., Story, G. M., Colley, S.,Hogenesch, J. B., McIntyre, P., Bevan, S. and Patapoutian,A. (2002). A heat-sensitive TRP channel expressed in keratinocytes. Science 296, 2046-2049. https://doi.org/10.1126/science.1073140
  56. Price, M. M., Oskeritzian, C. A., Milstien, S. and Spiegel, S.(2008). Sphingosine-1-phosphate synthesis and functions in mast cells. Future Lipidol. 3, 665-674. https://doi.org/10.2217/17460875.3.6.665
  57. Rukwied, R., Lischetzki, G., McGlone, F., Heyer, G. andSchmelz, M. (2000). Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. Br. J. Dermatol. 142, 1114-1120. https://doi.org/10.1046/j.1365-2133.2000.03535.x
  58. Ryu, S. D., Lee, H. S., Suk, H. Y., Park, C. S. and Choi, O. H.(2009). Cross-linking of FcepsilonRI causes $Ca^{2+}$ mobilization via a sphingosine kinase pathway in a clathrindependent manner. Cell Calcium. 45, 99-108. https://doi.org/10.1016/j.ceca.2008.07.002
  59. Schmelz, M. (2001). A neural pathway for itch. Nat. Neurosci. 4,9-10. https://doi.org/10.1038/82956
  60. Schworer, H. and Ramadori, G. (1995). Cholestatic pruritus--pathophysiology and therapy with special reference to treatment with 5-hydroxytryptamine subtype 3 receptor antagonists. Z. Gastroenterol. 33, 265-274.
  61. Shelley, W. B., Shelley, E. D. and Talanin, N. Y. (1996). Selfpotentiating allergic contact dermatitis caused by doxepin hydrochloride cream. J. Am. Acad. Dermatol. 34, 143-144. https://doi.org/10.1016/S0190-9622(96)90864-6
  62. Shimada, S. G., Shimada, K. A. and Collins, J. G. (2006).Scratching behavior in mice induced by the proteinaseactivated receptor-2 agonist, SLIGRL-NH2. Eur. J. Pharmacol.530, 281-283. https://doi.org/10.1016/j.ejphar.2005.11.012
  63. Sotomayor, S., Munoz-Moreno, L., Carmena, M. J., Schally, A.V., Sanchez-Chapado, M., Prieto, J. C. and Bajo, A. M.(2010). Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095). Int. J. Cancer. in press.
  64. Stander, S. and Steinhoff, M. (2002). Pathophysiology of pruritus in atopic dermatitis: an overview. Exp. Dermatol. 11, 12-24. https://doi.org/10.1034/j.1600-0625.2002.110102.x
  65. Steinhoff, M., Neisius, U., Ikoma, A., Fartasch, M., Heyer, G.,Skov, P. S., Luger, T. A. and Schmelz, M. (2003). Proteinaseactivated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J. Neurosci. 23, 6176-6180.
  66. Steinhoff, M., Vergnolle, N., Young, S. H., Tognetto, M.,Amadesi, S., Ennes, H. S., Trevisani, M., Hollenberg, M. D.,Wallace, J. L., Caughey, G. H., Mitchell, S. E., Williams, L.M., Geppetti, P., Mayer, E. A. and Bunnett, N. W. (2000).Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat. Med. 6, 151-158. https://doi.org/10.1038/72247
  67. Summey, B. T., Jr. and Yosipovitch, G. (2005). Pharmacologic advances in the systemic treatment of itch. Dermatol. Ther.18, 328-332. https://doi.org/10.1111/j.1529-8019.2005.00035.x
  68. Sun, Y. G. and Chen, Z. F. (2007). A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 448, 700-703. https://doi.org/10.1038/nature06029
  69. Sun, Y. G., Zhao, Z. Q., Meng, X. L., Yin, J., Liu, X. Y. and Chen,Z. F. (2009). Cellular basis of itch sensation. Science 325,1531-1534. https://doi.org/10.1126/science.1174868
  70. Swain, M. G. (2008). Gastrin-releasing peptide and pruritus: more than just scratching the surface. J. Hepatol. 48, 681-683. https://doi.org/10.1016/j.jhep.2008.01.007
  71. Taskapan, M. O. (2001). Zileuton and atopic dermatitis. Ann. Allergy Asthma. Immunol. 87, 162-163. https://doi.org/10.1016/S1081-1206(10)62213-2
  72. Tigyi, G. and Parrill, A. L. (2003). Molecular mechanisms of lysophosphatidic acid action. Prog. Lipid Res. 42, 498-526. https://doi.org/10.1016/S0163-7827(03)00035-3
  73. Tominaga, M., Ozawa, S., Ogawa, H. and Takamori, K. (2007).A hypothetical mechanism of intraepidermal neurite formation in NC/Nga mice with atopic dermatitis. J. Dermatol. Sci. 46, 199-210. https://doi.org/10.1016/j.jdermsci.2007.02.002
  74. Tsujii, K., Andoh, T., Lee, J. B. and Kuraishi, Y. (2008). Activation of proteinase-activated receptors induces itch-associated response through histamine-dependent and -independent pathways in mice. J. Pharmacol. Sci. 108, 385-388. https://doi.org/10.1254/jphs.08200SC
  75. Weidner, C., Klede, M., Rukwied, R., Lischetzki, G., Neisius, U.,Skov, P. S., Petersen, L. J. and Schmelz, M. (2000). Acute effects of substance P and calcitonin gene-related peptide in human skin-a microdialysis study. J. Invest. Dermatol. 115,1015-1020. https://doi.org/10.1046/j.1523-1747.2000.00142.x
  76. Weisshaar, E., Ziethen, B. and Gollnick, H. (1997). Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally-induced itch? Inflamm. Res. 46, 412-416. https://doi.org/10.1007/s000110050213
  77. Woodmansee, D. P. and Simon, R. A. (1999). A pilot study examining the role of zileuton in atopic dermatitis. Ann. Allergy Asthma. Immunol. 83, 548-552. https://doi.org/10.1016/S1081-1206(10)62868-2
  78. Yamaura, K., Oda, M., Suwa, E., Suzuki, M., Sato, H. and Ueno,K. (2009). Expression of histamine H4 receptor in human epidermal tissues and attenuation of experimental pruritus using H4 receptor antagonist. J. Toxicol. Sci. 34, 427-431. https://doi.org/10.2131/jts.34.427
  79. Yokoyama, Y., Yokoyama, T., Nagao, Y., Nakagawa, T. andMagaribuchi, T. (2009). Treatment of epidural morphine induced pruritus with butorphanol. Masui. 58, 178-182.
  80. Yosipovitch, G. and Papoiu, A. D. (2008). What causes itch in atopic dermatitis? Curr. Allergy. Asthma. Rep. 8, 306-311. https://doi.org/10.1007/s11882-008-0049-z
  81. Yosipovitch, G., Szolar, C., Hui, X. Y. and Maibach, H. (1996).High-potency topical corticosteroid rapidly decreases histamine-induced itch but not thermal sensation and pain in human beings. J. Am. Acad. Dermatol. 35, 118-120. https://doi.org/10.1016/S0190-9622(96)90524-1
  82. Yu, B., Shao, Y., Zhang, J., Dong, X. L., Liu, W. L., Yang, H.,Liu, L., Li, M. H., Yue, C. F., Fang, Z. Y., Zhang, C., Hu, X. P.,Chen, B. C., Wu, Q., Chen, Y. W., Zhang, W. and Wan, J.(2010). Polymorphisms in human histamine receptor H4 gene are associated with atopic dermatitis. Br. J. Dermatol.162, 1038-1043. https://doi.org/10.1111/j.1365-2133.2010.09675.x
  83. Zhang, X., Bao, L. and Ma, G. Q. (2010). Sorting of neuropeptides and neuropeptide receptors into secretory pathways. Prog. Neurobiol. 90, 276-283. https://doi.org/10.1016/j.pneurobio.2009.10.011
  84. Zylicz, Z., Krajnik, M., Sorge, A. A. and Costantini, M. (2003).Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J. Pain. Symptom. Manage 26, 1105-1112. https://doi.org/10.1016/j.jpainsymman.2003.05.004

Cited by

  1. Novel inhibitory effects of cardamonin on thromboxane A2-induced scratching response: Blocking of Gh/transglutaminase-2 binding to thromboxane A2 receptor vol.126, 2014, https://doi.org/10.1016/j.pbb.2014.09.011
  2. Neuroimmunological Mechanism of Pruritus in Atopic Dermatitis Focused on the Role of Serotonin vol.20, pp.6, 2012, https://doi.org/10.4062/biomolther.2012.20.6.506
  3. The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis vol.22, pp.13, 2021, https://doi.org/10.3390/ijms22137227